ArticleJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2017
Regulation of Cell Surface CB
Article in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 31 citations in OpenAlex.
- Unraveling Endocannabinoid Signaling Pathways in Cisplatin-Induced Ototoxicity.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Cannabidiol exerts antiinflammatory effects but maintains T effector memory cell differentiation in humans.JCI insight · 2026Article
- Chemical Probes for Investigating the Endocannabinoid System.Current topics in behavioral neurosciences · 2026Review
- Insights into cannabinoid receptor 2 (CB2) anterograde trafficking and pharmacological chaperoning.Cellular and molecular life sciences : CMLS · 2025Article
- Cannabis use associated with lower mortality among hospitalized Covid-19 patients using the national inpatient sample: an epidemiological study.Journal of cannabis research · 2024Article
- Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years.Pharmacological reviews · 2023Review
- Beta-Caryophyllene Modifies Intracellular Lipid Composition in a Cell Model of Hepatic Steatosis by Acting through CB2 and PPAR Receptors.International journal of molecular sciences · 2023Article
- Cannabinoid Analogue WIN 55212-2 Protects Paraquat-Induced Lung Injury and Enhances Macrophage M2 Polarization.Inflammation · 2022Article
- Endocannabinoid System and Tumour Microenvironment: New Intertwined Connections for Anticancer Approaches.Cells · 2021Review
- The Immune Endocannabinoid System of the Tumor Microenvironment.International journal of molecular sciences · 2020Review
- Cannabinoids, Inner Ear, Hearing, and Tinnitus: A Neuroimmunological Perspective.Frontiers in neurology · 2020Review
- Cannabinoid Receptor 2 (CBACS pharmacology & translational science · 2019Article
- Cannabinoid Receptor 2 Signalling Bias Elicited by 2,4,6-Trisubstituted 1,3,5-Triazines.Frontiers in pharmacology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Cannabinoid receptor type 2 (CB
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.